Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

BÜHLMANN fCAL® ELISA Citation:

 Beswick, L. et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study.  Journal of Crohn’s and Colitis. 2017 Nov 7. DOI: 10.1093/ecco-jcc/jjx146.  PMID:  29121178 .

Highlight from this Publication

“In ASUC, post-first dose IFX, early assessment of serum/faecal IFX, calprotectin and partial Mayo scores can accurate predict future remission and colectomy, thus potentially aid decision-making, i.e. accelerated IFX dosing or surgical planning if/when needed.”

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use.

Health Canada License: 80726